What is the recommended next step when a fourth‑generation HIV antigen/antibody ELISA screen is positive but a false‑positive result is suspected?

Management of Suspected False-Positive Fourth-Generation HIV Screening

When a fourth-generation HIV antigen/antibody ELISA screen is positive but false-positive is suspected, immediately perform an HIV-1/HIV-2 antibody differentiation immunoassay followed by HIV-1 RNA nucleic acid testing if the differentiation assay is negative or indeterminate. 1

Current Recommended Testing Algorithm

The CDC and Association of Public Health Laboratories recommend a specific sequence that does not require Western blot confirmation when using fourth-generation assays 1:

Step-by-Step Approach:

Initial Reactive Fourth-Generation Screen:

• If the fourth-generation antigen/antibody combination assay is reactive, proceed immediately to differentiation testing 1
• Do not wait for repeat screening on the same specimen
• Do not proceed directly to Western blot (this is outdated methodology) 1

Second Step - HIV-1/HIV-2 Differentiation Assay:

• Perform an antibody immunoassay that distinguishes HIV-1 from HIV-2 antibodies 1
• If differentiation assay is positive: The patient is HIV-infected; proceed with viral load and CD4 testing for management 1
• If differentiation assay is negative: Proceed immediately to HIV-1 RNA nucleic acid amplification testing (NAAT) 1
• If differentiation assay is indeterminate: Proceed to HIV-1 RNA NAAT 1

Third Step - HIV-1 RNA Testing (when differentiation is negative/indeterminate):

• Perform qualitative or quantitative HIV-1 RNA NAAT 1
• If RNA is positive (especially >100,000 copies/mL): Acute HIV-1 infection is confirmed 1
• If RNA is negative: The initial screening result was false-positive 1

Understanding False-Positive Results

Prevalence and Context:

• False-positive rates with fourth-generation assays range from 0.02% to 0.20% depending on the testing algorithm used 2, 3, 4
• In low HIV prevalence populations, false-positives can represent up to 29% of reactive screening results 5
• True false-positive results when both screening and confirmatory tests are reactive are extremely rare (approximately 1 in 135,187 in low-prevalence populations) 6

Signal-to-Cutoff (S/CO) Ratio Interpretation:

• False-positive results typically have low S/CO ratios (mean ~1.94), while true positives have markedly higher ratios (mean ~576) 4
• An S/CO ratio cutoff of 19.6 provides optimal discrimination (sensitivity 95.10%, specificity 99.99%) 4
• However, rare biological false-positives with very high S/CO ratios (>400) have been documented, emphasizing that no S/CO value alone can definitively exclude false-positivity 2
• False-positive rates are highest when S/CO is in the low range (1 to 5) 3

High-Risk Populations for False-Positive Results

Demographic Factors:

• Pregnant or parous women have higher rates of indeterminate and false-positive results compared to other populations 6, 7, 8
• Females have significantly higher false-positive rates (odds ratio 6.060) 5
• Age >60 years increases false-positive risk (odds ratio 6.983) 5
• Children (0-17 years) show higher false-positive incidence 4

Clinical Conditions Associated with False-Positives:

• Cancer patients (particularly those receiving plant alkaloid chemotherapy) 5
• Malignant tumors 4
• Digestive system disorders 4
• Pregnancy 8, 4
• Cerebral infarction 4
• Prior schistosomiasis infection 2
• Rare germ cell tumors 2

Critical Pitfalls to Avoid

Do Not Diagnose HIV Based on Screening Test Alone:

• A person should never be diagnosed with HIV infection based solely on a reactive fourth-generation screening test, regardless of S/CO value 9
• Even very high S/CO ratios can occasionally represent false-positives 2

Laboratory and Specimen Errors:

• Consider the possibility of mislabeled samples or laboratory errors, especially in patients with no identifiable HIV risk factors 6
• Incorrect results occur primarily from specimen-handling errors, laboratory errors, or failure to follow recommended testing algorithms 6

Special Consideration - HIV Vaccine Trial Participants:

• HIV vaccine-induced antibodies may cause false-positive results 6
• Vaccine trial participants with positive results should be referred back to their trial site for specialized testing and counseling 6

Management During Diagnostic Uncertainty

For Pregnant Women:

• Given the significance for reproductive decisions and need for antiretroviral therapy decisions, resolve uncertainties before final treatment decisions whenever possible 6
• Consider both additional testing and the woman's clinical condition and history of possible HIV exposure 6
• Pregnant women with repeatedly reactive screening tests but indeterminate supplemental tests should be retested to distinguish recent seroconversion from negative results 6
• Almost all HIV-infected persons develop detectable antibody within 1 month of exposure 6

Retesting with Second Specimen:

• Consider retesting with a second specimen for persons with positive confirmatory results at first testing to exclude specimen mislabeling 9
• This is particularly important for patients without identifiable HIV risk factors 6

Timeline Considerations

Window Period Awareness:

• Fourth-generation assays typically become positive 4-7 days after detectable virus by NAAT 1
• There is a 10-14 day period after infection when no markers are detectable 1
• If initial antibody, antigen, or RNA tests are negative but acute infection is suspected, retest 2-4 weeks later 1